A 63-year-old woman with metastatic breast cancer receives doxorubicin and cyclophosphamide. After 550 mg/m² cumulative doxorubicin dose, an echocardiogram shows an ejection fraction of 35% (baseline 60%). Which of the following agents could have reduced the risk of this complication if it had been co-administered from the first cycle?
- Dexrazoxane, an iron-chelating cardioprotectant (correct answer)
- Filgrastim, a granulocyte colony-stimulating factor
- Mesna, a uroprotective sulfhydryl compound
- Ondansetron, a serotonin-3 antagonist antiemetic
Explanation: When you encounter cardiotoxicity from chemotherapy, think about drug-specific protective agents and the mechanisms behind organ damage. Doxorubicin is an anthracycline antibiotic that causes dose-dependent cardiomyopathy through iron-catalyzed free radical formation, leading to irreversible myocardial damage. Dexrazoxane (choice A) is the correct answer because it's an iron-chelating agent specifically designed to prevent anthracycline-induced cardiotoxicity. It works by binding iron ions, preventing the formation of iron-doxorubicin complexes that generate cardiotoxic free radicals. Studies show it significantly reduces the risk of cardiomyopathy when given with each doxorubicin cycle, especially important at cumulative doses above 300 mg/m². Choice B (filgrastim) is incorrect because it's a G-CSF used to stimulate neutrophil production and prevent neutropenia—it has no cardioprotective properties. Choice C (mesna) protects against hemorrhagic cystitis from cyclophosphamide by neutralizing toxic metabolites in the bladder, but offers no cardiac protection against doxorubicin. Choice D (ondansetron) is an antiemetic that prevents chemotherapy-induced nausea and vomiting through 5-HT3 receptor antagonism—again, no cardiac benefit. Remember that organ-specific toxicities from chemotherapy have corresponding protective agents: dexrazoxane for doxorubicin's cardiac toxicity, mesna for cyclophosphamide's bladder toxicity, and leucovorin for methotrexate's folate antagonism. Match the protective agent to the specific drug and organ system at risk.